Epizyme (NASDAQ:EPZM) CEO Robert J. Gould sold 30,000 shares of the company’s stock on the open market in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $31.53, for a total transaction of $945,900.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Epizyme (NASDAQ:EPZM) traded down 1.61% on Monday, hitting $33.6895. The stock had a trading volume of 71,172 shares. Epizyme has a one year low of $18.10 and a one year high of $45.72. The stock has a 50-day moving average of $26.0 and a 200-day moving average of $26.53. The company’s market cap is $1.108 billion.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.47) by $0.25. Analysts expect that Epizyme will post $-1.78 EPS for the current fiscal year.
Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.
Receive News & Ratings for Epizyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.